Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Ovarian Neoplasms 5Breast Neoplasms 2SCLC, Extensive Stage 1Platinum-sensitive Relapsed Ovarian Cancer 1Glioblastoma 1Female Breast Cancer Patients 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Temozolomide 11Radiotherapy 4Magnetic Resonance Spectroscopy 4Specimen Handling 3Radiation 3Blood Specimen Collection 3Bevacizumab 3tislelizumab 2pembrolizumab 2cemiplimab 2Surgical Procedures, Operative 2mirdametinib 1gallium maltolate 1fluzoparib 1florbetapir 1elemene 1X-Rays 1Vortioxetine 1Transurethral Resection of Bladder 1Spironolactone 1Spinal Puncture 1Sitagliptin Phosphate 1Sampling Studies 1Receptors, Interleukin-8B 1Radiotherapy, Intensity-Modulated 1Psychosocial Intervention 1Platinum 1Photons 1Photochemotherapy 1Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Glioblastoma × fluzoparib × Clear all
NCT07047066 2025-07-02

A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma

Tongji Hospital

Phase 2 Not yet recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡